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Abstract 
Meta-analysing studies with low event rates is challenging as some of the standard methods for meta-
analysis are not well suited to handle rare outcomes. This is more evident when some studies have zero 
events in one or both treatment groups. In this article, we discuss why rare events require special 
attention in meta-analysis, we present an overview of some approaches suitable for meta-analysing rare 
events and we provide practical recommendations for their use.   
Methods  
We go through several models suggested in the literature for performing a rare events meta-analysis, 
highlighting their respective advantages and limitations. We illustrate these models using a published 
example from mental health. We provide the software code needed to perform all analyses in the 
appendix. 
Results  
Different methods may give different results, and using a suboptimal approach may lead to erroneous 
conclusions. When data is very sparse, the choice between the available methods may have a large 
impact on the results. Methods that use the so-called continuity correction (e.g. adding 0.5 to the number 
of events and non-events in studies with zero events in one treatment group) may lead to biased 
estimates.  
Conclusions 
Researchers should define the primary analysis a priori, in order to avoid selective reporting. A 
sensitivity analysis using a range of methods should be used to assess the robustness of results. 
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When the outcome of interest is rare, e.g. for the case of adverse events, individual studies are often 
underpowered to detect treatment effects. Pooling together evidence from multiple clinical trials via a 
meta-analysis offers a way to increase power1. Performing such meta-analyses, however, might be a 
methodologically challenging task, especially when some of the studies reported no events in one or 
both treatment arms (we will refer to such studies as single-zero and double-zero studies respectively). 
The issue of rare events is in itself quite frequent; an empirical study found that 30% of a random sample 
of 500 Cochrane reviews contained at least one trial with zero events in one arm2. It is important to note 
at this point that there is no universally accepted definition of what constitutes a rare event. Probably 
most researchers would agree that a risk smaller than 1% would be enough to classify an event as rare. 
However, at the meta-analysis level, and depending on the size of the relevant studies, higher event rates 
might also lead to zero events if the sample sizes are sufficiently small.  
Meta-analysing rare events requires special attention because standard methods are not well suited 
for the task. Probably the most popular method for performing a meta-analysis is the inverse variance 
method, either fixed-effect or using the DerSimonian and Laird random-effects model3,4. This method 
involves calculating a treatment effect separately from each study, along with a standard error. For 
binary outcomes the treatment effects are usually measured as odds ratios, risk ratios or risk differences. 
These study-specific estimates are then synthesized at a second level, across studies. An important aspect 
of the inverse variance method is that it uses a normal approximation of the true binomial likelihood 
(the ‘large sample approximation’). This approximation does not work well when event rates are low, 
while for studies with no events in one or both arms, calculating treatment effects in terms of odds or 
risk ratios becomes impossible since it involves division by zero.  
Consider for example the case of study 𝑖𝑖, which reported data in the form of the 2𝑥𝑥2 table shown in 
Table 1. The odds ratio 𝑂𝑂𝑅𝑅𝑖𝑖 for this study can be calculated as 𝑂𝑂𝑅𝑅𝑖𝑖 =
𝑎𝑎𝑖𝑖𝑑𝑑𝑖𝑖
𝑏𝑏𝑖𝑖𝑐𝑐𝑖𝑖
 and the corresponding 









.  It is easy to 
see that when no events are observed in one or both treatment groups (i.e .when 𝑎𝑎𝑖𝑖 = 0 and/or 𝑐𝑐𝑖𝑖 = 0) 
then the odds ratio, the standard error, or both cannot be calculated. The same problem is present when 
calculating risk ratios as well. Thus, when one or more of the entries of Table 1 is zero, the inverse 
variance method cannot be used. Note that the problem also appears when all patients had the event in 
one or both treatment groups (i.e .when 𝑏𝑏𝑖𝑖 = 0 and/or 𝑑𝑑𝑖𝑖 = 0) 
One easy way to overcome the zero-cell problem in single-zero studies is to ‘correct’ the data. This 
is done by adding a fixed value (typically 0.5) to all cells of Table 1, for studies with zero events in one 
of their arms. This so-called ‘continuity correction’ bypasses the problem caused by zero events, and 
allows the use of the standard inverse variance methods. Another simple solution to the problem is to 
completely forfeit the use of odds ratios and risk ratios, and only use risk difference to measure relative 
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effects. This would work because the risk difference does not suffer from computational problems in 
the presence of zero events. 
 Unfortunately, both aforementioned solutions (applying a continuity correction or using the risk 
difference) have been found to be problematic for the meta-analysis of rare events5. Simulations showed 
that using the inverse variance method after applying a 0.5 continuity correction leads to excess bias in 
the estimated effects. In addition it has been showed that when events are rare, risk difference methods 
have poor statistical properties (they provide too wide intervals and have low power), which makes them 
unsuitable for meta-analysis5.  
Double-zero studies are usually omitted from the meta-analysis (this is the default option for many 
statistical software). The Cochrane Handbook argues that such studies do not carry information 
regarding odds/risk ratios, and should therefore be excluded. Some researchers, however, pointed out 
that from an ethical point of view, patients in double-zero studies deserve to be included in the analyses6, 
while others discuss that such studies may carry information of relative treatment effects through their 
sample size7. 
One additional issue with rare events is that, for the case of random effects meta-analysis, the 
estimation of the variance of random effects (heterogeneity) may be biased8, which may lead to 
spuriously narrow confidence intervals. 
Thus, for the case of rare events meta-analysts need to resort to more advanced statistical methods. 
There are several alternatives that can be used to this end. In the Methods section of this paper we give 
a brief account of some of these methods. In the Results section we employ an example from a recent 
meta-analysis regarding mortality in antipsychotics9 to illustrate the methods that will be discussed.  
<<<TABLE 1 HERE>>> 
 
Methods 
In this section we go through some of the methods that have been proposed for the meta-analysis of 
rare events.  
I. Peto’s method 
Peto’s method10 can only be used to estimate odds ratios. It is by definition a fixed-effects method, 
i.e. it cannot account for heterogeneity between trials, which is one of the limitations of this model. 
Peto’s odds ratio follows an approach similar to the inverse variance model, but the effect estimate as 
well as the weight for each study are defined differently. The model incorporates evidence from single-
zero studies without having to resort to continuity corrections. Double-zero studies are excluded from 
the analysis. Thus, the only instance when Peto’s method runs into computational problems is when all 
studies in the meta-analysis are double-zero, i.e. when no events were observed in all studies. 
Simulations by Sweeting et al.11 and Bradburn et al.5 showed that the Peto odds ratio works reasonably 
well when the event is rare (< 1%), the treatment groups are balanced (i.e. there is approximately the 
same number of patients in the treatment and control arms within each study) and the effects are not 
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very large. If these conditions do not hold, Peto’s method may give biased results. For this reason 
Cochrane does not recommend Peto as the default approach for rare-events meta-analysis1. 
II. Mantel-Haenszel (MH) meta-analysis 
The MH method12 is a different approach to fixed-effects meta-analysis. It can be used for odds 
ratios, risk ratios or risk differences, and it uses a different weighting scheme for each measure. The 
method incorporates evidence from single-zero studies without requiring continuity corrections, unless 
the same cell of Table 1 is zero for all studies (e.g. when 𝑎𝑎𝑖𝑖 = 0 for all 𝑖𝑖). Thus, the method requires 
continuity corrections much less often. The MH method excludes from the analysis double-zero studies, 
unless risk difference is used. MH odds ratios have been shown to perform better than Peto’s method, 
in cases where the latter performed poorly (e.g. when the treatment groups are unbalanced)5. Cochrane’s 
software for meta-analyses (RevMan) uses MH as the default fixed-effect meta-analysis method. Note 
here that a random-effects MH approach is also implemented in RevMan 5. This however is not a ‘true’ 
MH model; it only uses the MH fixed-effect pooled result to estimate the heterogeneity, and then uses 
a DerSimonian and Laird (inverse variance) random-effects model. This means that this hybrid approach 
suffers from the usual problems that the inverse variance method faces when events are rare.  
III. Using a ‘treatment-arm’ continuity correction  
As we already discussed, a simple way to bypass the complications associated with zero events is to 
add 0.5 to all cells of Table 1 (i.e. to 𝑎𝑎𝑖𝑖, 𝑏𝑏𝑖𝑖, 𝑐𝑐𝑖𝑖 and 𝑑𝑑𝑖𝑖). This method, however, has been shown to perform 
poorly, i.e. it may give extremely biased results, especially when groups are unbalanced11. Sweeting et 
al.11 tried to mitigate these undesirable effects by using non-fixed corrections. In their approach, the 
continuity correction is different for each treatment arm of each study, and is inversely related to the 
size of the treatment arm. After implementing this correction to the data, standard approaches can be 
used for meta-analysis (e.g. inverse-variance, MH). The authors showed that a non-fixed continuity 
correction is preferable to the usual 0.5.  
However, the use of continuity corrections has been criticized, and it has been pointed out that this  
essentially arbitrary correction (0.5 or any other number) can affect the results of the meta-analysis6,7.  
IV. Logistic regression 
Logistic regression approaches use the correct binomial distribution of the data, and can be used to 
perform either a fixed or a random-effects meta-analysis. In this approach, single-zero studies are 
included without any continuity correction, while double-zero studies are excluded from the analysis. 
One general caveat of logistic regression is that in order to perform a random effects meta-analysis it is 
required to estimate the extent of heterogeneity of treatment effects, and this might be very difficult 
when events are rare8. Logistic regression (with unconditional binomial likelihood)  has been shown to 
perform similarly with the MH odds-ratio without continuity correction5. 
V. Bayesian meta-analysis 
Bayesian statistics is a branch of statistics in which the notion of probability corresponds to the state 
of knowledge regarding a certain phenomenon13, rather than the expected frequency of an event (which 
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corresponds to the so-called frequentist probability). Bayesian statistics are based in updating pre-
existing evidence in the light of new data. In a Bayesian analysis, for each quantity of interest (e.g. the 
treatment effects, or the extent of heterogeneity in a meta-analysis) we assign a prior distribution. This 
distribution quantifies our prior knowledge regarding this quantity, along with some uncertainty. In 
practice, for some of the parameters of a model there might be no prior knowledge or we may wish our 
priors to have a minimal effect on the model’s estimates. In such cases we can use ‘uninformative’ 
(‘vague’) distributions for these parameters.  
For a Bayesian meta-analysis one can use an adaptation of the simple logistic regression model14,15. 
This requires specifying prior distributions for all model parameters. When data is sparse, the choice of 
prior distributions can be very important. Even if a prior distribution is intended to be uninformative, it 
might have substantial impact on the results16. This is especially true for the case of specifying priors 
for heterogeneity in a random-effects meta-analysis17.  
This problem can be tackled by using reliable external information. For example, in a recent meta-
epidemiological study18,19, Turner et al. analysed data from 15,000 binary outcome meta-analyses from 
the Cochrane Database of Systematic Reviews. The authors then used results to formulate informative 
prior distributions for the extent of between-study heterogeneity. These distributions cover 80 different 
settings with respect to the outcome being assessed, the nature of the interventions being compared etc. 
Such informative distributions can be used as priors for a random-effects Bayesian meta-analysis, to 
overcome the problem of having ‘uninformative’ priors dominating results.  
VI. Beta-binomial with correlated responses 
The methods we have described up to this point (with the exception of the MH risk difference), 
exclude double-zero studies from the analyses. Kuss performed a simulation study7 to compare several 
methods for meta-analysing rare events that do not exclude double-zero studies and do not use continuity 
corrections. Based on these simulations, Kuss concluded that a beta-binomial model with correlated 
responses may be the best approach to meta-analysing rare events in studies with balanced treatment 
groups. This approach models the probability of an event in each treatment group of each study using a 
binomial likelihood, and then pools this probability for each group across studies using a bivariate 
(‘Sarmanov’) beta distribution20. The beta-binomial model can be used to estimate odds/risk ratios and 
risk differences, and is by definition a random-effects model.  
VII. Arcsine difference (AD) 
Rücker et al.21 proposed the use the arcsine difference for summarizing treatment effects. Their 
approach calculates the treatment effect from each study separately along with its standard error. This 
is done using a measure called arcsine difference, which is a function of 𝑎𝑎𝑖𝑖 , 𝑏𝑏𝑖𝑖, 𝑐𝑐𝑖𝑖 and 𝑑𝑑𝑖𝑖 of Table 1. The 
study-specific estimates of the arcsine difference are then combined using a standard fixed or random-
effects approach. The advantage of this approach is that it incorporates evidence from single- and 
double-zero studies without requiring a continuity correction. It can also provide an estimate even in the 
extreme case of having only double-zero studies in the meta-analysis, i.e. when there was no event in 
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any study. The major disadvantage of this method is that arcsine difference is very hard to interpret. 
Thus, this method has not been used in practice very often. It may however be valuable as a secondary 
analysis, to assess the robustness of results (e.g., when another method has detected a treatment effect). 
VIII. Other methods 
Several other models have appeared in the literature and can be used for the meta-analysis of rare 
events, such as an exact method based on combining confidence intervals22, a  bivariate binomial-normal 
model16, a hypergeometric-normal model16, a Poisson-gamma model23 and others. These methods have 
been rarely used in practice, and we will not consider them here in more detail.  
Illustrative case study 
In order to illustrate the methods that we discussed in this section, we used a set of previously 
published data regarding mortality risk in antipsychotics9. This comprised two independent meta-
analyses. The first one included 18 trials that compared long-acting injectable antipsychotics (LA-IAP) 
to placebo, for all-cause mortality. The event was very rare; the risk of death across both arms in all 
studies was around 0.2%. Only 7 events were reported in the drug arms (total 3774 patients) and 6 events 
in the placebo arm (2145 patients). The available data is summarized in Figure 1, where we also show 
the odds ratios and 95% Confidence Interval (CI) from each study, calculated using the large sample 
approximation. In this figure, in order to calculate odds ratios in single-zero studies we used a 0.5 
continuity corrections, for illustration purposes. No odds ratios are shown for double-zero studies. The 
second meta-analysis compared LA-IAP to oral antipsychotics (OAP) for all-cause mortality. A total of 
24 studies were included, reporting 15 deaths in LA-IAP (4059 patients) and 24 deaths in OAP (3820 
patients). The total risk of death across both arms was around 0.5%. Figure 2 shows the available data.  
In the original publication9, the authors performed both meta-analyses using the standard inverse-
variance method, with a 0.5 continuity correction for single-zero studies. Here we re-analysed this data 
using a range of different methods. As we have already discussed, risk difference has been shown to 
perform poorly when it comes to meta-analysing rare events5, and we did not consider it here. Moreover, 
when the probability of an event is low, the difference between risk ratios and odds ratios becomes 
negligible. Thus, we only focused on odds ratios – an analysis of risk ratios would give almost identical 
results. For the Bayesian random-effects meta-analyses we used informative prior distributions for 
heterogeneity, based on the empirical study by Turner et al.19. For the first meta-analysis (LA-IAP vs 
placebo) we used the distribution corresponding to all-cause mortality, for pharmacological 
interventions vs. placebo. For the second meta-analysis (LA-IAP vs OAP) we used the distribution 
corresponding to all-cause mortality, for pharmacological vs. pharmacological interventions (Table IV 
in 19).  
All analyses were performed using freely available software (R24 and OpenBUGS24). All software 
codes we used as well as some additional details regarding fitting the models are given in the Appendix. 
FIGURE 1 HERE 
FIGURE 2 HERE 
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Table 2 summarizes results from all analyses. It is evident that the choice of the method for meta-
analysis is more important in the first example (LAI-AP vs placebo) as compared to the second (LAI-
AP vs OAP). This is because events in the first dataset were sparser. In fact, out of the 18 studies of the 
LAI-AP vs placebo dataset only 1 had events in both arms – the rest were either single-zero (9 studies) 
or double-zero (8 studies). Conversely, in the second dataset there were 7 studies with events in both 
arms, 8 single-zero and 9 double-zero studies. This finding highlights a more general conclusion, i.e. 
the sparser the data, the larger the impact of the choice of meta-analysis method.  
If we focus on the first example we can easily see that using a continuity correction (either 0.5 as in 
the original paper, or the treatment-arm continuity correction11) leads to narrower CIs compared to other 
methods, i.e. larger precision in the results. This should come as no surprise, as this method in essence 
imputes data in single-zero studies. Thus, this increase in precision is artificial. Moreover, it is obvious 
that different choices of the continuity correction lead to different results.  
In the same example, the Peto method gives similar, but not identical results to Mantel-Haenszel with 
no continuity correction. A look at the data might convince us that Peto’s method is suboptimal for this 
particular example, as there are studies with large imbalances, e.g. there are studies with 3:1 
randomization ratio.  
The fixed-effect Bayesian model gave almost identical results to the Mantel-Haenszel approach 
(without continuity correction). The effect of modeling random effects was rather minimal in both 
analyses, as the estimated value for heterogeneity was small (detailed results in the Appendix).  
The beta-binomial with correlated responses model failed to converge for the first example. This 
highlights one of the potential disadvantages of this model, as compared to the other approaches. For 
the second example it gave results comparable to the rest of the methods. 
Finally, in Table 2 we also show the results from the arcsine difference meta-analysis. It should be 
obvious that interpreting this effect measure in a clinically meaningful way can be very difficult. 
TABLE 2 HERE 
 
Discussion 
Different methods for meta-analysing rare events may lead to different conclusions, and the sparser 
the data the larger the differences between the results of the alternative methods. This was highlighted 
in a much-publicized meta-analysis regarding the effects of rosiglitazone on the risk of myocardial 
infarction and death. The original meta-analysis25 gave results very close to the conventional threshold 
of ‘statistical significance’ (i.e. p-value<0.05). Subsequent meta-analyses of the same dataset using 
alternative methods led to (slightly) different results than the original publication23,26, which had an 
impact on the statistical significance of the findings. 
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This ambiguity stems from the fact that there is currently no clear answer as to which is the best 
model for meta-analysing rare events. Different models employ different assumptions, whose validity 
is usually difficult (or even impossible) to assess. Keeping that in mind, we highlight several general 
considerations that researchers can take into account when setting off to perform a meta-analysis of rare 
events: 
1. The use of artificial continuity corrections should be avoided (with an exception perhaps for 
visualizing evidence7, e.g. as we did in Figures 1 and 2).  
2. Risk difference is usually not the optimal effect measure to use.  
3. Peto’s method should not be employed when the three conditions needed are not met (event 
rates<1%, balanced groups, small treatment effects). In such circumstances the Mantel-
Haenszel odds-ratios without continuity correction performs better than Peto. 
4. The beta-binomial model has been shown in simulations to outperform other methods in 
some settings7, but might suffer from issues regarding convergence of the model.  
5. Bayesian meta-analysis with informative prior distributions is a good way to include 
random-effects in the meta-analysis. This is because it overcomes the problem of estimating 
heterogeneity when events are sparse.  
6. Results regarding relative effects (odds/risk ratios) should always be presented along with 
absolute incidence rates, to put results into context27. A risk ratio of 1.5 might have very 
different clinical implications when the risk in the control group is 5% and when it is 0.1%.  
7. Meta-analysts should avoid labelling results as statistically significant or non-significant. 
The use of p-values thresholds to dichotomize findings has recently attracted a lot of 
criticism28. Particularly for the case of rare-events meta-analysis, the use of arbitrary cut-
points for p-values (such as the usual 0.05 or any other threshold29) can be even more 
problematic, because results might be affected by the choice of model – as was the case in 
the rosiglitazone example.  
Finally, researchers should predefine an analysis plan a priori (e.g. at the protocol), to avoid selective 
use of methods. In addition, when events are rare, meta-analysts should always perform extensive 
sensitivity analyses using a range of alternative models, to ensure the robustness of their results. When 
results are very sensitive to the choice of model researchers should be particularly cautious on how they 
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Table 1: Data provided by study i, in the form of a 2x2 table 
Study i Events No events 
Experimental ai bi 
Control ci di 
 
 
Table 2: Results from two sets of meta-analyses, using a range of different methods. An OR<1 or an 
arcsine difference<0 in the X vs Y comparison indicate that treatment X is safer (lower risk of death). 
LAI-AP: long-acting injectable antipsychotics, OAP: oral antipsychotics, OR: odds ratios. CI: 
confidence interval. CrI: credible interval. 
Method used LAI-AP vs placebo LAI-AP vs OAP 





 [0.38; 1.34] 
Inverse variance OR with treatment-arm continuity 
correction 
 (95% CI) 
0.70 




























Bayesian meta-analysis, random effects OR 
 (95% CrI) 
0.71 
 [0.22, 2.31] 
0.63 
[0.32, 1.24] 
Beta-binomial model, OR  
(95% CI) - 
0.63  
[0.29, 1.34] 
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Figure 1: Summary of the available studies for all-cause mortality, for long acting injectable 
antipsychotics (LAI-AP) vs. placebo. For illustration purposes, in order to calculate odds ratios (OR) 
and Confidence Intervals (CI) in single-zero studies we have used a 0.5 continuity correction. For 
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Figure 2: Summary of the available studies for all-cause mortality, for long acting injectable 
antipsychotics (LAI-AP) vs. oral antipsychotics (OAP). For illustration purposes, in order to calculate 
odds ratios (OR) and Confidence Intervals (CI) in single-zero studies we have used a 0.5 continuity 
correction. For double-zero studies no effect is shown. 
 
